National Healthcare Security Administration official Shi Zihai: The 11th batch of centralized procurement will no longer be based solely on the lowest price.

Deputy Director Shi Zihai of the National Medical Insurance Administration stated at the series of themed press conferences on "high-quality completion of the '14th Five-Year Plan" held on July 24 that the 11th batch of centralized procurement has recently been initiated. In terms of selection rules, the "anchor point" for optimizing price difference calculation has been improved, no longer using the lowest price as a reference. At the same time, the lowest bidding company must publicly explain the reasonableness of their bid and commit to not bidding below cost; in terms of quality assurance, it is required that the production line of the bidding drugs has not violated the drug production quality management norms in the past two years. The drug regulatory department will conduct a full inspection and product sampling of the selected enterprises in the centralized procurement, with higher requirements in this regard than before.